The Technical Analyst
AMERICAN BRIVISION [ABVC]
Exchange: PNK Industry: Biotechnology
AMERICAN BRIVISION Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: SELL (auto-tracking)
29.81% $1.350
America/New_York / 23 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 14.26 mill |
| EPS: | -2.43 |
| P/E: | -0.560 |
| Earnings Date: | May 13, 2024 |
| SharesOutstanding: | 10.56 mill |
| Avg Daily Volume: | 0.745 mill |
| RATING 2024-04-23 |
|---|
| B- |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Sell | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Buy | |
| P/E: | Neutral | |
| Price To Book: | Neutral |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.560 | sector: PE -11.58 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0x |
| Company: PE -0.560 | industry: PE -107.25 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$-0.476 (-135.27%) $-1.826 |
| Date: 2024-04-23 |
| Expected Trading Range (DAY) |
|---|
|
$ 1.244 - 1.436 ( +/- 7.16%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2022-05-20 | Jiang Shuling | Buy | 0 | Common Stock |
| 2021-08-02 | An Chihliang | Sell | 0 | Common Stock |
| 2021-08-02 | Sakamoto Norimi | Buy | 0 | |
| 2021-08-02 | Odaira Yoshinobu | Sell | 0 | Common Stock |
| 2021-08-02 | Jiang Tsung Shann | Buy | 0 | Common Stock |
| INSIDER POWER |
|---|
| 0.00 |
| Last 77 transactions |
| Buy: 22 119 096 | Sell: 9 170 000 |
Forecast:
16:00 - $1.350
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $1.350
Forecast 2: 16:00 - $1.350
Forecast 3: 16:00 - $1.350
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $1.350 (29.81% ) |
| Volume | 7.14 mill |
| Avg. Vol. | 0.745 mill |
| % of Avg. Vol | 957.83 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For ABVC
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:34 | sell | $1.300 | N/A | Active |
|---|
ABVC
ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase I/II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for attention deficit hyperactivity disorder; ABV-1703 has completed Phase I clinical trials for the treatment of pancreatic cancer; ABV-1702 has completed Phase I clinical trials to treat myelodysplastic syndromes; ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients; and ABV-1701 Vitargus for the treatment of retinal detachment or vitreous hemorrhage. It has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California. ABVC BioPharma, Inc. is a subsidiary of YuanGene Corporation.
Latest Press Releases
2024-04-18 09:25:00 - Press Release
Aibtl Biopharma Inc. Acquired Tt Life Company, Valued At $8.33m, With 1.66m Aibtl Shares At $5 Per Share
Fremont, ca, april 18, 2024 (globe newswire) -- via newmediawire — abvc biopharma, inc. (nasdaq: abvc) ("company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, cns (central nervous systems), and oncology/hematology, announced today that the company's subsidiary aibtl biopharma inc. acquired tt life company, an established player in the precision medicine industry. the acquisition includes malaysian import trading company, direct sales company, and taiwanese direct sales company, which are estimated to be approximately equivalent to $8.33m. aibtl purchased 100% shares of tt life by swapping its 1.66m shares at $5 per share. this strategic move positions aibtl to expand its portfolio further and accelerate innovation in the rapidly growing precision medicine market while consolidating the financials, including the revenue, profit, and cash flow, with tt life.
2024-04-17 09:00:00 - Press Release
Abvc Biopharma Executes A Global Licensing Definitive Agreement For The Treatment Of Nsclc, Expecting Aggregate Income Of $13.75m And Royalties Of Up To $12.50m
Fremont, ca, april 17, 2024 (globe newswire) -- via newmediawire -- abvc biopharma, inc. (nasdaq: abvc) ("company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, cns (central nervous systems), and oncology/hematology, announced today that the company, together with its affiliate rgene corporation entered into a comprehensive licensing agreement with oncox, a private company registered in the british virgin islands that specializes in dietary supplements for oncology. we are hopeful that this agreement will facilitate the advancement of treatments for non-small cell lung cancer (nsclc) since it covers the license for the clinical trial, registration, manufacturing, supply, and distribution rights of abvc's single-herb botanical drug extract from the dry fruit body of maitake mushroom (grifola frondosa) for treatment of non-small cell lung cancer...
2024-04-10 08:30:00 - Press Release
Abvc Biopharma Executes A Global Licensing Term Sheet For Oncology/hematology Products, Expecting Licensing Income Of $55m And Royalties Of Up To $50m
Fremont, ca, april 10, 2024 (globe newswire) -- via newmediawire -- abvc biopharma, inc. (nasdaq: abvc) ("company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, cns (central nervous systems), and oncology/hematology, announced today that the company together with its affiliates biolite, inc., and rgene corporation entered into a term sheet with oncox biopharma, inc. (oncox) for the company's oncology/hematology pipeline(the "licensed products"). subject to negotiation and execution of the definitive agreement, this license would cover the licensed products' clinical trial, registration, manufacturing, supply, and distribution rights. abvc is set to receive $50,000,000 as licensing fees in the form of cash/shares within 30 days of execution of the definitive agreement, with an additional milestone payment of $5,000,000 in cash after the first fundraising round and royalties of 5% of net sales, up to $50,000,000, after the launch of the licensed products.
2024-03-26 08:30:00 - Press Release
Abvc Biopharma Entered Into A Global Licensing Deal Of Vitargus With Licensing Income Of $33.5m And Royalties Up To $60m
Fremont, ca, march 26, 2024 (globe newswire) -- via newmediawire – abvc biopharma, inc. (nasdaq: abvc) ("company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, cns (central nervous systems), and oncology/hematology, announced today that each of the company and its subsidiary biofirst corporation entered into a global licensing agreement with forseecon eye corporation (feye) for the company's ophthalmology pipeline, which includes the medical device vitargus® (valued at $187m, by third-party valuer) (the "licensed products"). this license will cover the licensed products' clinical trial, registration, manufacturing, supply, and distribution rights.
2024-03-19 08:30:00 - Press Release
Abvc Biopharma, Inc. Ceo Selected As 2024 Top 10 Ceo In Ceo Insights Asia Magazine
Fremont, ca, march 19, 2024 (globe newswire) -- via newmediawire -- abvc biopharma, inc. (nasdaq: abvc) ("company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, cns, and ophthalmology, proudly announced today that its ceo, dr. uttam patil, was selected as one of the top 10 ceos in taiwan 2024 by ceo insights asia magazine . this recognition is a testament to dr. patil's outstanding leadership, innovative vision, and significant contributions to the company. dr. patil is confident in the company's prospects, so he owns stock options without claiming a salary. within his first year as the company's ceo, the company saw a rise in the stock price of its common stock, an increase in its social media presence, and a renewed focus on its essential products.
Latest News
2023-10-26 11:00:20 - PennyStocks
Best Penny Stocks To Buy Now? 4 Biotech Stocks To Watch
If you're wondering what is going on in the stock market today or which penny stocks to buy now that major indexes are lower, you're not alone. Earnings season mixed with economic data has resulted in a sharp downturn for the market.
2023-01-06 06:00:00 - PennyStocks
How to Find Cheap Penny Stocks to Make Money Trading
Use these tips for finding cheap penny stocks to buy The post How to Find Cheap Penny Stocks to Make Money Trading appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
2023-01-05 09:39:05 - PennyStocks
5 Hot Penny Stocks Exploding After News This Week
Hot penny stocks with news to watch this week. The post 5 Hot Penny Stocks Exploding After News This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
2022-03-23 09:25:00 - GlobeNewsWire
ABVC BioPharma to Present at the Maxim Group 2022 Virtual Growth Conference
Fremont, CA, March 23, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced that the company will be participating at the Maxim Group 2022 Virtual Growth Conference, taking place March 28-30, 2022.
2021-12-12 20:55:35 - Pulse2
ABVC Biopharma Stock (ABVC): Why The Price Increased
The stock price of ABVC Biopharma Inc (NASDAQ: ABVC) increased by 5.14% in the previous trading session. This is why it happened.
2021-12-10 13:38:41 - Benzinga
Why ABVC BioPharma Shares Are Trading Higher On Friday?
ABVC BioPharma Inc (NASDAQ: ABVC) shares gained during the market trading session on continued momentum from yesterday's dietary supplement distribution deal and after a favorable report from Zacks Small-Cap Research. Yesterday, ABVC Biopharma announced that BioKey would produce dietary supplements derived from the maitake mushroom in tablet and liquid forms.
2021-11-01 13:19:43 - PennyStocks
Hot Reddit Penny Stocks to Watch That Exploded Today
Check these Reddit penny stocks out for your watchlist in November The post Hot Reddit Penny Stocks to Watch That Exploded Today appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
2021-11-01 11:32:49 - InvestorPlace
ABVC Stock: The Social Media Chatter That Has ABVC BioPharma Shooting 250% Higher Today
ABVC BioPharma (ABVC) stock is rocketing higher on Monday as investors on social media hype up the shares despite a lack of news. The post ABVC Stock: The Social Media Chatter That Has ABVC BioPharma Shooting 250% Higher Today appeared first on InvestorPlace.
2021-11-01 10:48:26 - Invezz
ABVC Biopharma stock is up 275% on Monday: explained here
Shares of ABVC Biopharma Inc (NASDAQ: ABVC) are on fire this morning. The stock jumped nearly 300% on Monday as retail traders on StockTwits picked ABVC Biopharma as their next favourite.
2021-11-01 06:16:30 - Pulse2
ABVC Stock: Why The Price Surged Today
The stock price of ABVC Biopharma Inc (NASDAQ: ABVC) increased by over 300% pre-market today. This is why it happened.